Musculoskeletal Health in Premature Ovarian Insufficiency. Part Two: Bone

Abstract

Accelerated bone loss and muscle loss coexist in women with premature ovarian insufficiency (POI), but there are significant gaps in our understanding of musculoskeletal health in POI. This review describes estrogen signaling in bone and its role in skeletal health and disease. Possible mechanisms contributing to bone loss in different forms of POI and current evidence regarding the utility of available diagnostic tests and therapeutic options are also discussed. A literature review from January 2000 to March 2020 was conducted to identify relevant studies. Women with POI experience significant deterioration in musculoskeletal health due to the loss of protective effects of estrogen. In bone, loss of bone mineral density (BMD) and compromised bone quality result in increased fracture risk; however, tools to assess bone quality such as trabecular bone score (TBS) need to be validated in this population. Timely initiation of HRT is recommended to minimize the deleterious effects of estrogen deficiency on bone in the absence of contraindications; however, the ideal estrogen replacement regimen remains unknown. POI is associated with compromised bone health, regardless of the etiology. Ongoing research is warranted to refine our management strategies to preserve bone health in women with POI.

Keywords

premature ovarian insufficiency - osteoporosis - bone - muscle - early menopause

Publikationsverlauf

Artikel online veröffentlicht:
30. März 2021

• References

• 1 Webber L, Davies M, Anderson R. et al; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31 (05) 926-937
• 2 Nguyen HH, Milat F, Vincent A. Premature ovarian insufficiency in general practice: meeting the needs of women. Aust Fam Physician 2017; 46 (06) 360-366
• 3 Gibson-Helm M, Teede H, Vincent A. Symptoms, health behavior and understanding of menopause therapy in women with premature menopause. Climacteric 2014; 17 (06) 666-673
• 4 Bachelot A, Rouxel A, Massin N. et al; POF-GIS Study Group. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol 2009; 161 (01) 179-187
• 5 Popat VB, Calis KA, Kalantaridou SN. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99 (09) 3418-3426
• 6 Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996; 65 (02) 337-341
• 7 Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016; 101 (09) 3497-3505
• 8 Crofton PM, Evans N, Bath LE. et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Obstet Gynecol Surv 2011; 66 (06) 348-350
• 9 Hansen S, Brixen K, Gravholt CH. Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT. J Bone Miner Res 2012; 27 (08) 1794-1803
• 10 Shevroja E, Lamy O, Kohlmeier L, Koromani F, Rivadeneira F, Hans D. Use of trabecular bone score (TBS) as a complementary approach to dual-energy X-ray absorptiometry (DXA) for fracture risk assessment in clinical practice. J Clin Densitom 2017; 20 (03) 334-345
• 11 Almeida M, Laurent MR, Dubois V. et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 2017; 97 (01) 135-187
• 12 Hassler N, Roschger A, Gamsjaeger S. et al. Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res 2014; 29 (10) 2144-2151
• 13 van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003; 24 (06) 782-801
• 14 Börjesson AE, Lagerquist MK, Liu C. et al. The role of estrogen receptor α in growth plate cartilage for longitudinal bone growth. J Bone Miner Res 2010; 25 (12) 2690-2700
• 15 Wang J, Stern PH. Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts. J Cell Biochem 2011; 112 (12) 3714-3721
• 16 Manolagas SC, Almeida MS. Gonadal steroids. In: Bilezikian JP, Bouillon R, Clemens T. et al, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley; 2018: 194-204
• 17 Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab 2012; 23 (11) 576-581
• 18 Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21 (02) 115-137
• 19 Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332 (05) 305-311
• 20 Määttä JA, Büki KG, Gu G. et al. Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice. FASEB J 2013; 27 (02) 478-488
• 21 Melville KM, Kelly NH, Khan SA. et al. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J Bone Miner Res 2014; 29 (02) 370-379
• 22 Li JY, Tawfeek H, Bedi B. et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A 2011; 108 (02) 768-773
• 23 Henning P, Ohlsson C, Engdahl C. et al. The effect of estrogen on bone requires ERα in nonhematopoietic cells but is enhanced by ERα in hematopoietic cells. Am J Physiol Endocrinol Metab 2014; 307 (07) E589-E595
• 24 Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31 (03) 266-300
• 25 Lean JM, Davies JT, Fuller K. et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003; 112 (06) 915-923
• 26 Almeida M, Han L, Martin-Millan M. et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282 (37) 27285-27297
• 27 Frost HM. On the estrogen-bone relationship and postmenopausal bone loss: a new model. J Bone Miner Res 1999; 14 (09) 1473-1477
• 28 Wergedal JE, Kesavan C, Brommage R, Das S, Mohan S. Role of WNT16 in the regulation of periosteal bone formation in female mice. Endocrinology 2015; 156 (03) 1023-1032
• 29 Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S. Mechanosensation and transduction in osteocytes. Bone 2013; 54 (02) 182-190
• 30 van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003; 14 (06) 525-530
• 31 Popat VB, Calis KA, Vanderhoof VH. et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009; 94 (07) 2277-2283
• 32 Leite-Silva P, Bedone A, Pinto-Neto AM, Costa JV, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet 2009; 280 (02) 177-181
• 33 Sun L, Peng Y, Sharrow AC. et al. FSH directly regulates bone mass. Cell 2006; 125 (02) 247-260
• 34 Khosla S. Estrogen versus FSH effects on bone metabolism: evidence from interventional human studies. Endocrinology 2020; 161 (08) bqaa111
• 35 Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006; 103 (40) 14925-14930
• 36 Faienza MF, Brunetti G, Ventura A. et al. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's syndrome. Bone 2015; 81: 228-236
• 37 Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 1991; 87 (01) 81-83
• 38 Sybert VP, McCauley E. Turner's syndrome. N Engl J Med 2004; 351 (12) 1227-1238
• 39 Wolff DJ, Van Dyke DL, Powell CM. Working Group of the ACMG Laboratory Quality Assurance Committee. Laboratory guideline for Turner syndrome. Genet Med 2010; 12 (01) 52-55
• 40 Jacobs P, Dalton P, James R. et al. Turner syndrome: a cytogenetic and molecular study. Ann Hum Genet 1997; 61 (Pt 6): 471-483
• 41 Gravholt CH, Fedder J, Naeraa RW, Müller J. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab 2000; 85 (09) 3199-3202
• 42 Gravholt CH, Andersen NH, Conway GS. et al; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177 (03) G1-G70
• 43 Nguyen HH, Wong P, Strauss BJ. et al. Delay in estrogen commencement is associated with lower bone mineral density in Turner syndrome. Climacteric 2017; 20 (05) 436-441
• 44 Högler W, Briody J, Moore B, Garnett S, Lu PW, Cowell CT. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J Clin Endocrinol Metab 2004; 89 (01) 193-199
• 45 Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Res 2014; 7 (01) 12
• 46 Coss KP, Doran PP, Owoeye C. et al. Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis 2013; 36 (01) 21-27
• 47 Han TS, Cadge B, Conway GS. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome. Clin Endocrinol (Oxf) 2006; 65 (05) 643-647
• 48 Vincent AJ, Nguyen HH, Ranasinha S, Vollenhoven B. Increased detection of co-morbidities with evaluation at a dedicated adult Turner syndrome clinic. Climacteric 2017; 20 (05) 442-447
• 49 Bakalov VK, Bondy CA. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord 2008; 9 (02) 145-151
• 50 Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab 2002; 87 (06) 2798-2808
• 51 Costa AM, Lemos-Marini SH, Baptista MT, Morcillo AM, Maciel-Guerra AT, Guerra Jr G. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients. J Bone Miner Metab 2002; 20 (05) 294-297
• 52 Holroyd CR, Davies JH, Taylor P. et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int 2010; 21 (12) 2093-2099
• 53 Bechtold S, Rauch F, Noelle V. et al. Musculoskeletal analyses of the forearm in young women with Turner syndrome: a study using peripheral quantitative computed tomography. J Clin Endocrinol Metab 2001; 86 (12) 5819-5823
• 54 Soucek O, Lebl J, Snajderova M. et al. Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages. Clin Endocrinol (Oxf) 2011; 74 (04) 445-452
• 55 Soucek O, Schönau E, Lebl J, Sumnik Z. Artificially low cortical bone mineral density in Turner syndrome is due to the partial volume effect. Osteoporos Int 2015; 26 (03) 1213-1218
• 56 Nour MA, Burt LA, Perry RJ, Stephure DK, Hanley DA, Boyd SK. Impact of growth hormone on adult bone quality in Turner syndrome: a HR-pQCT study. Calcif Tissue Int 2016; 98 (01) 49-59
• 57 Wasserman H, Backeljauw PF, Khoury JC, Kalkwarf HJ, Gordon CM. Bone fragility in Turner syndrome: fracture prevalence and risk factors determined by a national patient survey. Clin Endocrinol (Oxf) 2018; 89 (01) 46-55
• 58 Soucek O, Schönau E, Lebl J, Willnecker J, Hlavka Z, Sumnik Z. A 6-year follow-up of fracture incidence and volumetric bone mineral density development in girls with Turner syndrome. J Clin Endocrinol Metab 2018; 103 (03) 1188-1197
• 59 Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf) 1999; 51 (04) 497-502
• 60 Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K, Christiansen JS. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 2003; 59 (01) 89-96
• 61 Nissen N, Gravholt CH, Abrahamsen B. et al. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. Clin Endocrinol (Oxf) 2007; 67 (06) 897-903
• 62 Barrientos-Rios R, Frias S, Velázquez-Aragón JA. et al. Low bone mineral density and renal malformation in Mexican patients with Turner syndrome are associated with single nucleotide variants in vitamin D-metabolism genes. Gynecol Endocrinol 2019; 35 (09) 772-776
• 63 Peralta López M, Miras M, Silvano L. et al. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab 2011; 24 (5-6): 307-312
• 64 Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51 (02) 147-158
• 65 Shi K, Liu L, He YJ. et al. Body composition and bone mineral status in patients with Turner syndrome. Sci Rep 2016; 6: 38026
• 66 Yeşilkaya E, Bereket A, Darendeliler F. et al. Turner syndrome and associated problems in Turkish children: a multicenter study. J Clin Res Pediatr Endocrinol 2015; 7 (01) 27-36
• 67 El-Mansoury M, Barrenäs M-L, Bryman I. et al. Chromosomal mosaicism mitigates stigmata and cardiovascular risk factors in Turner syndrome. Clin Endocrinol (Oxf) 2007; 66 (05) 744-751
• 68 Rajpathak SN, Vellarikkal SK, Patowary A, Scaria V, Sivasubbu S, Deobagkar DD. Human 45,X fibroblast transcriptome reveals distinct differentially expressed genes including long noncoding RNAs potentially associated with the pathophysiology of Turner syndrome. PLoS One 2014; 9 (06) e100076
• 69 Panis B, Forget PP, van Kroonenburgh MJ. et al. Bone metabolism in galactosemia. Bone 2004; 35 (04) 982-987
• 70 Kaufman FR, Loro ML, Azen C, Wenz E, Gilsanz V. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia. J Pediatr 1993; 123 (03) 365-370
• 71 van Erven B, Welling L, van Calcar SC. et al. Bone health in classic galactosemia: systematic review and meta-analysis. JIMD Rep 2017; 35: 87-96
• 72 Batey LA, Welt CK, Rohr F. et al. Skeletal health in adult patients with classic galactosemia. Osteoporos Int 2013; 24 (02) 501-509
• 73 Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D. et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet 1999; 83 (04) 322-325
• 74 Allen EG, Sullivan AK, Marcus M. et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007; 22 (08) 2142-2152
• 75 Davies JH, Evans BA, Jenney ME, Gregory JW. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy. Bone 2002; 31 (02) 319-326
• 76 Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 2009; 27 (22) 3605-3610
• 77 Hadji P, Gnant M, Body JJ. et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. Cancer Treat Rev 2012; 38 (06) 798-806
• 78 Shapiro CL, Halabi S, Hars V. et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47 (05) 683-689
• 79 Torino F, Barnabei A, De Vecchis L. et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol 2014; 89 (01) 27-42
• 80 Zhao J, Liu J, Chen K. et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2014; 145 (01) 113-128
• 81 Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43 (02) 183-190
• 82 Fogelman I, Blake GM, Blamey R. et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14 (12) 1001-1006
• 83 Shiba E, Yamashita H, Kurebayashi J. et al. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer 2016; 23 (03) 499-509
• 84 Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14 (01) 78-84
• 85 Pagani O, Regan MM, Walley BA. et al; TEXT and SOFT Investigators, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371 (02) 107-118
• 86 Francis PA, Pagani O, Fleming GF. et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379 (02) 122-137
• 87 Ramchand SK, Cheung YM, Grossmann M. Bone health in women with breast cancer. Climacteric 2019; 22 (06) 589-595
• 88 Wright LE. Radiotherapy-induced osteoporosis. In: Bilezikian JP, Bouillon R, Clemens T. et al, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley; 2018: 788-792
• 89 Wright LE, Buijs JT, Kim HS. et al. Single-limb irradiation induces local and systemic bone loss in a murine model. J Bone Miner Res 2015; 30 (07) 1268-1279
• 90 Georgiou KR, Hui SK, Xian CJ. Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells 2012; 1 (03) 205-224
• 91 Kotsopoulos J, Hall E, Finch A. et al. Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation. JAMA Netw Open 2019; 2 (08) e198420
• 92 Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS. Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 2016; 23 (11) 1228-1232
• 93 Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric 2011; 14 (04) 445-452
• 94 Fakkert IE, Abma EM, Westrik IG. et al. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 2015; 51 (03) 400-408
• 95 Hayirlioglu A, Gökaslan H, Andaç N. The effect of bilateral oophorectomy on bone mineral density. Rheumatol Int 2006; 26 (12) 1073-1077
• 96 Vesco KK, Marshall LM, Nelson HD. et al; Study of Osteoporotic Fractures. Surgical menopause and nonvertebral fracture risk among older US women. Menopause 2012; 19 (05) 510-516
• 97 Fakkert IE, Teixeira N, Abma EM, Slart R, Mourits M, de Bock GH. Bone mineral density and fractures after surgical menopause: systematic review and meta-analysis. BJOG 2017; 124 (10) 1525-1535
• 98 Yildiz A, Sahin I, Göl K, Taner Z, Ulutürk A, Biberoĝlu K. Bone loss rate in the lumbar spine: a comparison between natural and surgically induced menopause. Int J Gynaecol Obstet 1996; 55 (02) 153-159
• 99 Kiriakova V, Cooray SD, Yeganeh L, Somarajah G, Milat F, Vincent AJ. Management of bone health in women with premature ovarian insufficiency: Systematic appraisal of clinical practice guidelines and algorithm development. Maturitas 2019; 128: 70-80
• 100 Watts NB. Bone quality: getting closer to a definition. J Bone Miner Res 2002; 17 (07) 1148-1150
• 101 Shuhart CR, Yeap SS, Anderson PA. et al. Executive summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 2019; 22 (04) 453-471
• 102 Ferrari S, Bianchi ML, Eisman JA. et al; IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012; 23 (12) 2735-2748
• 103 Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7 (02) 137-145
• 104 Feil K, Zippl AL, Toth B. Premature ovarian failure: ESHRE guidelines and current studies. J Gynakologische Endokrinologie 2019; 29 (03) 69-75
• 105 Nguyen HH, Wong P, Strauss BJ, Ebeling PR, Milat F, Vincent A. A cross-sectional and longitudinal analysis of trabecular bone score in adults with turner syndrome. J Clin Endocrinol Metab 2018; 103 (10) 3792-3800
• 106 Faulkner KG, Wacker WK, Barden HS. et al. Femur strength index predicts hip fracture independent of bone density and hip axis length. Osteoporos Int 2006; 17 (04) 593-599
• 107 Lewiecki EM. Clinical vignettes: using non-BMD measurements in clinical practice. Clin Rev Bone Miner Metab 2016; 14 (01) 50-54
• 108 Nishiyama KK, Dall'Ara E, Engelke K. Advanced techniques of bone mass measurements and strength in adults. In: Bilezikian JP, Bouillon R, Clemens T. et al, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley; 2018: 260-271
• 109 Miljkovic I, Kuipers AL, Cauley JA. et al; Osteoporotic Fractures in Men Study Group. Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. J Gerontol A Biol Sci Med Sci 2015; 70 (09) 1133-1140
• 110 Vierucci F, Del Pistoia M, Erba P, Federico G, Saggese G. Usefulness of phalangeal quantitative ultrasound in identifying reduced bone mineral status and increased fracture risk in adolescents with Turner syndrome. Hormones (Athens) 2014; 13 (03) 353-360
• 111 Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11 (04) 281-294
• 112 Gallicchio CT, Figueiredo-Alves ST, Prendin Tórtora R, Mendonça LM, Farias ML, Guimarães MM. Effect of puberty on the relationship between bone markers of turnover and bone mineral density in Turner's syndrome. Horm Res 2004; 61 (04) 193-199
• 113 Goh M, Nguyen HH, Khan NN, Milat F, Boyle JA, Vincent AJ. Identifying and addressing osteoporosis knowledge gaps in women with premature ovarian insufficiency and early menopause: a mixed-methods study. Clin Endocrinol (Oxf) 2019; 91 (04) 498-507
• 114 Vujovic S, Brincat M, Erel T. et al; European Menopause and Andropause Society. EMAS position statement: managing women with premature ovarian failure. Maturitas 2010; 67 (01) 91-93
• 115 Pitkin J, Rees MC, Gray S. et al. Management of premature menopause. Menopause Int 2007; 13 (01) 44-45
• 116 Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open 2017; 2017 (02) hox007
• 117 Nakamura T, Tsuburai T, Tokinaga A. et al. Efficacy of estrogen replacement therapy (ERT) on uterine growth and acquisition of bone mass in patients with Turner syndrome. Endocr J 2015; 62 (11) 965-970
• 118 Cintron D, Rodriguez-Gutierrez R, Serrano V, Latortue-Albino P, Erwin PJ, Murad MH. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis. Endocrine 2017; 55 (02) 366-375
• 119 Prior JC, Vigna YM, Wark JD. et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997; 12 (11) 1851-1863
• 120 Castelo-Branco C, Rovira M, Pons F. et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996; 23 (03) 307-312
• 121 Burgos N, Cintron D, Latortue-Albino P. et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine 2017; 58 (03) 413-425
• 122 Gazarra LBC, Bonacordi CL, Yela DA, Benetti-Pinto CL. Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives. Menopause 2020; 27 (10) 1110-1116
• 123 Davey DA. HRT: some unresolved clinical issues in breast cancer, endometrial cancer and premature ovarian insufficiency. Womens Health (Lond) 2013; 9 (01) 59-67
• 124 Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012; 15 (Suppl. 01) 11-17
• 125 Sas TC, de Muinck Keizer-Schrama SM, Stijnen T. et al; Dutch Advisory Group on Growth Hormone. Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner's syndrome participating in a randomized dose-response study. Pediatr Res 2001; 50 (03) 417-422
• 126 Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab 1993; 76 (04) 861-866
• 127 Carrascosa A, Gussinyé M, Terradas P, Yeste D, Audí L, Vicens-Calvet E. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. J Bone Miner Res 2000; 15 (10) 2005-2010
• 128 Bakalov VK, Van PL, Baron J, Reynolds JC, Bondy CA. Growth hormone therapy and bone mineral density in Turner syndrome. J Clin Endocrinol Metab 2004; 89 (10) 4886-4889
• 129 Suganuma N, Furuhashi M, Hirooka T. et al. Bone mineral density in adult patients with Turner's syndrome: analyses of the effectiveness of GH and ovarian steroid hormone replacement therapies. Endocr J 2003; 50 (03) 263-269
• 130 Marino R, Misra M. Bone health in primary ovarian insufficiency. Semin Reprod Med 2011; 29 (04) 317-327
• 131 Davis SR, van der Mooren MJ, van Lunsen RH. et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13 (03) 387-396
• 132 Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019; 7 (10) 754-766
• 133 Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9 (22) 1-160
• 134 Winters-Stone KM, Dobek J, Nail LM. et al. Impact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial. Osteoporos Int 2013; 24 (05) 1637-1646
• 135 Milat F, Vincent AJ. Management of bone disease in women after breast cancer. Climacteric 2015; 18 (Suppl. 02) 47-55
• 136 Hershman DL, McMahon DJ, Crew KD. et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26 (29) 4739-4745
• 137 Gnant M, Mlineritsch B, Schippinger W. et al; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360 (07) 679-691
• 138 Kim JE, Ahn JH, Jung KH. et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 2011; 125 (01) 99-106
• 139 Gnant M, Mlineritsch B, Luschin-Ebengreuth G. et al; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9 (09) 840-849
• 140 Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006; 17 (02) 313-316
• 141 Silverman SL, Christiansen C, Genant HK. et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23 (12) 1923-1934
• 142 Tashjian Jr AH, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006; 21 (03) 354-365
• 143 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377 (15) 1417-1427